1. Home
  2. NVCR vs EVO Comparison

NVCR vs EVO Comparison

Compare NVCR & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$13.57

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.12

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVCR
EVO
Founded
2000
1993
Country
Switzerland
Germany
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.1B
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
NVCR
EVO
Price
$13.57
$3.12
Analyst Decision
Buy
Strong Buy
Analyst Count
6
1
Target Price
$28.42
$7.00
AVG Volume (30 Days)
1.8M
251.3K
Earning Date
10-30-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$642,269,000.00
$887,396,457.00
Revenue This Year
$9.75
N/A
Revenue Next Year
$5.62
$8.52
P/E Ratio
N/A
N/A
Revenue Growth
11.17
N/A
52 Week Low
$10.70
$2.84
52 Week High
$32.06
$5.00

Technical Indicators

Market Signals
Indicator
NVCR
EVO
Relative Strength Index (RSI) 59.44 50.32
Support Level $12.30 $3.03
Resistance Level $13.97 $3.05
Average True Range (ATR) 0.55 0.09
MACD 0.09 0.03
Stochastic Oscillator 77.21 80.42

Price Performance

Historical Comparison
NVCR
EVO

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: